TherapeuticsMD, Inc. (TXMD)

The investment case here is fundamentally broken. The company has endured a catastrophic nine-year decline, with the stock losing 99.7% of its value over the trailing period. The most damning evidence is the seven consecutive years of negative annual returns ending recently; this is not a temporary setback but a structural implosion of the business model. Fundamentals confirm the distress: the company is burning cash with negative operating margins, shrinking revenues, and negative earnings growth. There is no dividend to provide income, and the balance sheet offers no safety net against continued deterioration. While the forward P/E looks cheap at under 6x, this is a classic value trap where the denominator (earnings) is negative or expected to remain so for the foreseeable future, rendering the metric meaningless. The recent news of a large institutional stake by Baselake Group is likely a contrarian accumulation of distressed assets or a hedge against further decline, not a signal of imminent recovery. Options data reinforces this bearish sentiment, with traders buying deep out-of-the-money puts to cap losses rather than betting on a rally. With no catalyst visible to reverse the multi-year downtrend and the statistical forecast showing zero directional bias, the prudent move is to stay away from this sinking ship.